Alzheimer’s Disease Stem Cell Therapy Development

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the accumulation of beta-amyloid plaques and tau tangles in the brain, leading to cognitive decline and memory loss. Stem cell therapy has emerged as a promising approach to treat AD by replacing damaged or lost neurons and promoting brain regeneration. CD BioSciences offers stem cell therapy development services for AD, dedicating to advancing the therapeutic development of the disease.

Overview of Alzheimer's Disease

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that affects the brain's ability to function properly, leading to a decline in cognitive and memory functions. It is the most common cause of dementia, accounting for up to 80% of all dementia cases.

AD is characterized by the accumulation of beta-amyloid plaques and tau protein tangles in the brain, which leads to the death of brain cells and a loss of connections between them. As the disease progresses, symptoms worsen and can include confusion, memory loss, mood changes, difficulty with language and communication, and difficulty with daily activities.

The exact cause of AD is not fully understood, but age, genetics, and environmental factors are believed to play a role. There is currently no cure for AD, and treatment options are limited to managing symptoms and improving quality of life. Early diagnosis and management of AD can help slow the progression of the disease and improve quality of life for patients and their families. Research into the underlying mechanisms of AD and potential treatments, including stem cell therapy, is ongoing.

Stem Cells Therapy for Alzheimer's Disease

Stem cell therapy strategy for Alzheimer's disease (Qin, Chuan et al., 2022)

• Neurogenesis/Synaptogenesis
  Transplanted stem cells contribute to hippocampal neurogenesis and synaptic plasticity. For examples, hUCB-MSCs stimulate neurogenesis and synaptic plasticity through paracrine GDF-15. AD-MSCs improve endogenous neurogenesis in both the subgranular and subventricular zones and BM-MSCs promote hippocampal neurogenesis.
• Amyloid-β and Tau Pathologies
  Deposition of Aβ aggregates and formation of neurogenic fiber tangles are associated with neuronal death and synaptic loss. The administration of hUCB-MSCs reduced tau hyperphosphorylation and improved memory impairment in mice. And transplantation of hAM-MSC reduces Aβ deposition and improves memory function.
• Inflammation and Immunoregulation
  The therapeutic effects of BM-MSCs involve immunomodulatory mechanisms, including peripheral monocyte recruitment, M1/M2 polarization of microglia, pro/anti-inflammatory cytokines, and neurotrophin-mediated synaptic plasticity.
• Paracrine and Autocrine Cytokines
  Injected hUCB-MSCs can secrete paracrine GDF-15 in the hippocampus of APP/PS1 transgenic mice, thereby promoting neurogenesis and synaptogenesis.
• Enhancement of Synapse Formation
  Transplanted BM-MSCs have an effect on synapse formation and endogenous neurogenesis. Potential mechanisms include production of neurotrophic factors and proliferation of regulatory T cells.

Our Services

CD Biosciences offers Alzheimer's disease stem cell therapy development services. Meaningful data indicates that stem cell transplantation attenuates neuropathology and significantly improves cognitive deficits in animal models of Alzheimer's disease. Workflow of our services are as follows:

As a pioneer in biotechnology, CD BioSciences has grown into one of the largest independent biotechnology companies in the world. CD BioSciences is committed to providing professional and efficient service to our customers around the world. If you are interested in our service, please contact us.

Reference

1. Qin, Chuan et al. "Stem cell therapy for Alzheimer's disease: An overview of experimental models and reality." Animal models and experimental medicine vol. 5,1 (2022): 15-26.